EUVIMEDEUVIMED entdecken
Übersichtsarbeit

[18F]-Fluorodeoxyglucose PET in Lymphoma

Sanaz Katal, Ali Gholamrezanezhad, Ali Bazargan, Constantine Tam, Kim Taubman, Rodney John Hicks

PET Clinics · 2026-11

DOI: 10.1016/j.cpet.2026.09.017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PET Clinics, 2026-11. Verfasst von Sanaz Katal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Imaging and Theranostics, Melbourne Theranostic Innovation Centre (MTIC), Melbourne, Victoria, Australia. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

[18F]-fluorodeoxyglucose (FDG) PET/computed tomography is central to the management of FDG-avid lymphomas, providing whole-body assessment of viable metabolic disease across staging, treatment planning, and response evaluation. Its clinical value lies not simply in detecting residual metabolic activity, but in interpreting PET findings according to lymphoma subtype, treatment context, and their therapeutic consequences. Emerging quantitative biomarkers, long-axial field-of-view PET, and target-specific tracers may further characterize disease burden, heterogeneity, and therapeutic vulnerability, extending PET beyond conventional metabolic imaging toward more individualized and increasingly theranostic lymphoma management.

Schlagwörter

Stichwörter der Autor:innen

Deauville scoreFDG PET/CTLong-axial field-of-view PETLymphomaResponse-adapted therapyTheranosticsTotal metabolic tumor volume

Autor:innen und Institutionen

  • Department of Molecular Imaging and Theranostics, Melbourne Theranostic Innovation Centre (MTIC), Melbourne, Victoria, Australia.
  • Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: Ali.Gholamrezanezhad@cshs.org.
  • Department of Hematology, St Vincent's Hospital Melbourne and Department of Medicine, The University of Melbourne Melbourne, Victoria, Australia.
  • Department of Hematology, St Vincent's Hospital Melbourne, Head of Lymphoma Service, Alfred Health, Peter Maccallum Cancer Centre, Melbourne, Victoria Australia.
  • Department of Nuclear Medicine and PET, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
  • Department of Medicine, The University of Melbourne and Monash University, Founder, Melbourne Theranostic Innovation Centre (MTIC), Melbourne, Victoria, Australia.

Zitieren

APA

Katal, S., Gholamrezanezhad, A., Bazargan, A., Tam, C., Taubman, K., & Hicks, R. J. (2026). [18F]-Fluorodeoxyglucose PET in Lymphoma. PET Clinics. https://doi.org/10.1016/j.cpet.2026.09.017

Vancouver

Katal S, Gholamrezanezhad A, Bazargan A, Tam C, Taubman K, Hicks RJ. [18F]-Fluorodeoxyglucose PET in Lymphoma. PET Clinics. 2026. doi:10.1016/j.cpet.2026.09.017

BibTeX
@article{Katal2026,
  author = {Katal, Sanaz and Gholamrezanezhad, Ali and Bazargan, Ali and Tam, Constantine and Taubman, Kim and Hicks, Rodney John},
  title = {[18F]-Fluorodeoxyglucose PET in Lymphoma},
  journal = {PET Clinics},
  year = {2026},
  doi = {10.1016/j.cpet.2026.09.017}
}
Kostenlos starten →